Doxorubicin Loaded Liposomal Nanoparticles Containing Quantum Dot for Treatment of Breast Cancer

Authors

  • Amir Heydari Nasab Department of Chemical Engineering, Tehran Science and Research Branch, Islamic Azad University, Tehran, I.R. IRAN
  • Azim Akbarzadeh Department of Nanobiotechnology, Pasteur Institute of Iran, Tehran, I.R. IRAN
  • Javad Shahabi Department of Chemical Engineering, Tehran Science and Research Branch, Islamic Azad University, Tehran, I.R. IRAN
  • Mehdi Ardjmand Department of Chemical Engineering, South Tehran Branch, Islamic Azad University, Tehran, I.R. IRAN
Abstract:

In addition to increasing the efficacy of various drugs, Nanoparticles reduce their side effects. In this study, different nanoparticle formulations of Doxorubicin anticancer drugs were prepared. The efficacy of the formulations produced in the cell culture medium was studied compared with the free drug. Reverse phase evaporation was used to form the liposome containing doxorubicin. The graphite nanoparticles were prepared. These nanoparticles were mixed with the liposome containing doxorubicin, and the related Nano-complex was conjugated. Spectroscopy methods for visible light-ultraviolet, light and light dynamics differentiation were used to describe nanoparticles. For the toxicity of different formulation, MTT and MCF-7 cells were used. The amount of drug loading in the liposomes was 72%. The largest amount was related to the Nano-conjugated complex and the smallest size was related to the graphene-oxide nanoparticle with a nanometer size. The controlled release in 96 hours and the amount of drug release was 95.43%. Doxorubicin-containing liposome toxicity was 75% and Nano- conjugated complex was 85%, at the lowest drug concentration (10µM). The free drug created 35% cell toxicity in 10µM and 89% in 2500µM. The results of the study showed Liposomes act as a suitable nanoparticle for doxorubicin. It was found that the effect of nanoparticles of graphene oxide is very important. In the presence of this nanoparticle in the complex, toxicity increased significantly.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Therapy with liposomal doxorubicin in patients with advanced breast cancer after treatment with classical doxorubicin

Breast cancer is the most common female cancer in the world and in Poland. The improvement of diagnostic and therapeutic methods has led to patients’ longer life expectancy. It has also made breast cancer a chronic disease, increasing the risk of late side effects of oncological therapy. More cardiovascular diseases are diagnose in patients over 65 with an oncological history than in those with...

full text

Substituting Doxorubicin with Nonpegylated Liposomal Doxorubicin for the Treatment of Early Breast Cancer: Results of a Retrospective Study

Introduction. Evidence from the metastatic setting suggests that replacing conventional doxorubicin with nonpegylated liposomal doxorubicin (NPLD) for early breast cancer may maintain efficacy whilst reducing long-term cardiotoxicity, an important consideration with many patients going on to receive multiple lines of treatment. Methods. Consecutive patients with early breast cancer treated with...

full text

Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer.

In this study, we report the design and delivery of a tumor-targeted, pH-responsive quantum dot-mucin1 aptamer-doxorubicin (QD-MUC1-DOX) conjugate for the chemotherapy of ovarian cancer. To achieve active cancer targeting, QD was conjugated with a DNA aptamer specific for mutated MUC1 mucin overexpressed in many cancer cells including ovarian carcinoma. DOX was attached to QD via a pH-sensitive...

full text

Immunotherapy for Breast Cancer Treatment

Breast cancer, as a heterogeneous disease, includes a wide range of pathological and clinical behaviors. Current treatment protocols, including radiotherapy, chemotherapy, and hormone replacement therapy, are mainly associated with poor response and high rate of recurrence. Therefore, more efforts are needed to develop alternative therapies for this type of cancer. Immunotherapy, as a novel str...

full text

Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.

BACKGROUND Based on preclinical studies and a phase I trial of the combination of bortezomib and pegylated liposomal doxorubicin (PLD), which both showed activity in breast cancer, we conducted a phase II study of this regimen in patients with metastatic breast cancer. PATIENTS AND METHODS Patients received bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of an every-21-day cycle, along with PLD ...

full text

New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin.

Metastatic breast cancer (MBC) remains a major cause of morbidity and mortality in women worldwide. For three decades doxorubicin, alone or in combination with other cytotoxic agents, has been a mainstay of systemic therapy for MBC. However, its use is limited by cumulative cardiotoxicity. More recently liposomal formulations of doxorubicin have been developed which exhibit equal efficacy but r...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 38  issue 5

pages  45- 51

publication date 2019-10-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023